Skip to content
value.today
Assembly Biosciences, Inc. logo

Assembly Biosciences, Inc.

ASMB
$434 Mmarket cap on Oct 21, 2026+718.7% since Jan 2024
Compare
World rank
#13,202
Revenue
$72 M
For year ending December-2025
Net income
$-6 M
-8.5% margin
SEC filing
Employees
—

Assembly Biosciences, Inc. in brief

Assembly Biosciences, Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. It was founded in 2005. Its market value was $434 M on 21 October 2026, which makes it the 13,202nd largest listed company in the world and the 2,623rd largest in the USA on this site. In the year to December 2025 it had sales of $72 M and a net loss of $6 M. Jason A. Okazaki is its chief executive. Its shares trade under the symbol ASMB (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Assembly Biosciences, Inc.

Assembly Biosciences is an Ambitious Clinical Stage Biopharmaceutical company. The company annual revenue is 16 million USD and 115 as on 2020. The headquarters is in USA.

Assembly Biosciences, Inc. timeline

5 events, 2005–2020
  1. 2005
  2. 🏁
    · approximate
    Founded
  3. 2008
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2010
  6. 🔔
    Initial public offering as Ventrus Biosciences Inc
    Final prospectus filed with the SEC on 17 December 2010; shares registered for exchange trading on 10 December 2010.
  7. 2014
  8. ✎
    Renamed Assembly Biosciences, Inc.
    Formerly Ventrus Biosciences Inc.
  9. 2020
  10. 💰
    Record revenue of $79 million
    FY2020, the highest of the 7 years on record.

Events of Assembly Biosciences, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$175 M$350 M$525 M$700 M2020202120222023202420252026

World rank over time

▼ down 3,604 places since 2020
2020-01-01: #9632#9,63220202021-01-01: #15502#15,50220212022-01-07: #22703#22,70320222022-12-25: #24188#24,18820222023-07-30: #24477#24,47720232024-01-05: #24645#24,64520242026-03-08: #7357#7,35720262026-08-01: #12069#12,06920262026-10-21: #13236#13,2362026

Rank in USA: #2,269 (Jan 2020) · #3,237 (Jan 2021) · #4,406 (Jan 2022) · #4,643 (Dec 2022) · #4,632 (Jul 2023) · #4,032 (Jan 2024) · #1,296 (Mar 2026) · #2,509 (Aug 2026) · #2,626 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
6.5×
Price / book
2.1×
Free cash flow yield
-9.5%
Net margin (TTM)
-16.6%
Operating margin
-16.8%
Return on equity
-5.4%
Liabilities / assets
19.7%
Revenue growth
+153.5%
R&D / revenue
89.6%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $15M, net income $-91M$15MFY18Fiscal year ending Dec 2019: revenue $16M, net income $-98M$16MFY19Fiscal year ending Dec 2020: revenue $79M, net income $-62M$79MFY20Fiscal year ending Dec 2021: revenue $6M, net income $-130M$6MFY21Fiscal year ending Dec 2022: revenue —, net income $-93M—FY22Fiscal year ending Dec 2023: revenue $7M, net income $-61M$7MFY23Fiscal year ending Dec 2024: revenue $29M, net income $-40M$29MFY24Fiscal year ending Dec 2025: revenue $72M, net income $-6M$72MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$72M+153.5%$-12M$-6M-8.5%
Dec 2024$29M+298.3%$-45M$-40M-140.9%
Dec 2023$7M—$-65M$-61M-855.2%
Dec 2022——$-94M$-93M—
Dec 2021$6M-92.1%$-133M$-130M-2077.8%
Dec 2020$79M+395.6%$-65M$-62M-78.6%
Dec 2019$16M+7.8%$-103M$-98M-611.7%
Dec 2018$15M—$-93M$-91M-613.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-41M$0M$-41M$-0.55—
Dec 2024$-51M$0M$-51M$-6.69—
Dec 2023$23M$0M$22M$-13.38—
Dec 2022$-84M$0M$-85M$-23.08—
Dec 2021$-93M$3M$-97M$-3.00—
Dec 2020$-63M$0M$-63M$-1.75—
Dec 2019$-84M$2M$-86M$-3.72—
Dec 2018$-65M$0M$-65M$-3.98—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$67M
Net income, trailing 12 months
$-11M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $7M, net income $-10M$7MDec ’24Three months to Mar 2025: revenue $9M, net income $-9M$9MMar ’25Three months to Jun 2025: revenue $10M, net income $-10M$10MJun ’25Three months to Sep 2025: revenue $11M, net income $-9M$11MSep ’25Three months to Dec 2025 (from the annual report): revenue $42M, net income $22M$42MDec ’25Three months to Mar 2026: revenue $8M, net income $-9M$8MMar ’26Three months to Jun 2026: revenue $13M, net income $-4M$13MJun ’26Three months to Sep 2026: revenue $3M, net income $-20M$3MSep ’26

Latest quarter to Sep 2026: revenue $3M (-72.6% on a year earlier), net income $-20M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Assembly Biosciences, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$72 M
Operating income
$-12 M
Net income
$-6 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$258 M
Total liabilities
$51 M
Total equity
$207 M

As of December-2025

Top 100 institutional investors in Assembly Biosciences, Inc.#

As of Sep 30, 2026
104 institutions held 19.2 M shares (about 93.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 66.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Assembly Biosciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Gilead Sciences, Inc.4,977,0890 (0.00%)24.31%$117 MNov 6, 2026
2Farallon Capital Management, L.L.C.1,604,5900 (0.00%)7.84%$38 MNov 16, 2026
3Paradigm Biocapital Advisors LP1,553,7480 (0.00%)7.59%$36 MNov 16, 2026
4BlackRock, Inc.1,488,018+721,199 (+94.05%)7.27%$35 MNov 13, 2026
5Ra Capital Management, L.P.1,020,4100 (0.00%)4.98%$24 MNov 16, 2026
6Parkman Healthcare Partners LLC796,256+75,075 (+10.41%)3.89%$19 MNov 16, 2026
7Vanguard Capital Management LLC602,932+43,990 (+7.87%)2.94%$14 MNov 13, 2026
8State Street Corp559,590+387,659 (+225.47%)2.73%$13 MNov 12, 2026
9Millennium Management LLC490,137+191,330 (+64.03%)2.39%$12 MNov 16, 2026
10Commodore Capital LP461,922-953,078 (-67.36%)2.26%$11 MNov 16, 2026
11Seven Fleet Capital Management LP417,441-15,706 (-3.63%)2.04%$10 MNov 16, 2026
12Citadel Advisors LLC379,812+283,905 (+296.02%)1.85%$9 MNov 16, 2026
13Point72 Asset Management, L.P.362,728-97,865 (-21.25%)1.77%$9 MNov 16, 2026
14Geode Capital Management, LLC361,152+80,728 (+28.79%)1.76%$8 MNov 6, 2026
15Ameriprise Financial Inc288,397+58,397 (+25.39%)1.41%$7 MNov 16, 2026
16HRT Financial LP230,777New1.13%$5 MNov 13, 2026
17Schonfeld Strategic Advisors LLC228,002-14,151 (-5.84%)1.11%$5 MNov 16, 2026
18DV Equities, LLC226,4150 (0.00%)1.11%$5 MNov 16, 2026
19Squadron Capital Management LLC225,000+65,000 (+40.62%)1.10%$5 MNov 16, 2026
20Goldman Sachs Group Inc191,747+53,914 (+39.12%)0.94%$5 MNov 16, 2026
21B Group, Inc.175,7060 (0.00%)0.86%$4 MNov 16, 2026
22Janus Henderson Group Ltd.164,142—0.80%$4 MNov 16, 2026
23Woodline Partners LP150,7800 (0.00%)0.74%$4 MNov 16, 2026
24Northern Trust Corp142,299+19,270 (+15.66%)0.69%$3 MNov 16, 2026
25Driehaus Capital Management LLC128,307-21,693 (-14.46%)0.63%$3 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Assembly Biosciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Vanguard Portfolio Management LLC124,931+33,778 (+37.06%)0.61%$3 MNov 13, 2026
27Qube Research & Technologies Ltd114,422+62,934 (+122.23%)0.56%$3 MNov 13, 2026
28Franklin Templeton Inc113,2000 (0.00%)0.55%$3 MNov 12, 2026
29Renaissance Technologies LLC112,017+72,576 (+184.01%)0.55%$3 MNov 12, 2026
30Vanguard Fiduciary Trust Co95,578+21,608 (+29.21%)0.47%$2 MNov 13, 2026
31HighVista Strategies LLC93,224+19,819 (+27.00%)0.46%$2 MNov 13, 2026
32Nuveen, LLC85,906+69,031 (+409.07%)0.42%$2 MNov 10, 2026
33Squarepoint Ops LLC73,732+39,518 (+115.50%)0.36%$2 MNov 9, 2026
34Morgan Stanley69,111+23,892 (+52.84%)0.34%$2 MNov 13, 2026
35Los Angeles Capital Management LLC60,342New0.29%$1 MNov 12, 2026
36Trexquant Investment LP57,147+11,486 (+25.15%)0.28%$1 MNov 16, 2026
37Monimus Capital Management, LP47,5800 (0.00%)0.23%$1 MNov 16, 2026
38Jump Financial, LLC45,898New0.22%$1 MNov 13, 2026
39Charles Schwab Investment Management Inc39,202+10,074 (+34.59%)0.19%$1 MNov 16, 2026
40Arrowstreet Capital, Limited Partnership38,857New0.19%$1 MNov 13, 2026
41Gsa Capital Partners LLP38,286-4,645 (-10.82%)0.19%$1 MNov 16, 2026
42BNP Paribas Financial Markets34,995+10,792 (+44.59%)0.17%$1 MNov 12, 2026
43Man Group plc34,713New0.17%$1 MNov 16, 2026
44Wellington Management Group LLP34,685New0.17%$1 MNov 16, 2026
45UBS Group AG33,125-8,681 (-20.76%)0.16%$1 MNov 10, 2026
46Bank of New York Mellon Corp32,972+8,957 (+37.30%)0.16%$1 MNov 5, 2026
47Connor, Clark & Lunn Investment Management Ltd.32,652+8,887 (+37.40%)0.16%$1 MNov 10, 2026
48XTX Topco Ltd30,777-12,141 (-28.29%)0.15%$1 MNov 16, 2026
49Engineers Gate Manager LP30,650+12,884 (+72.52%)0.15%$1 MNov 16, 2026
50FMR LLC28,560+28,382 (+15944.94%)0.14%$1 MNov 10, 2026
51HSBC Holdings PLC28,405+11,470 (+67.73%)0.14%$1 MNov 16, 2026
52Massachusetts Financial Services Co /ma/28,126New0.14%$1 MNov 12, 2026
53Quadrature Capital Ltd25,413New0.12%$1 MNov 13, 2026
54Bank Of America Corp /de/25,303+15,736 (+164.48%)0.12%$1 MNov 16, 2026
55ADAR1 Capital Management, LLC21,447+1,000 (+4.89%)0.10%$1 MNov 16, 2026
56Jane Street Group, LLC21,201New0.10%$0 MNov 12, 2026
57Ally Bridge Group (NY) LLC18,298-121,702 (-86.93%)0.09%$0 MNov 16, 2026
58American Century Companies Inc17,869+4,630 (+34.97%)0.09%$0 MNov 12, 2026
59Barclays PLC16,838+10,705 (+174.55%)0.08%$0 MNov 6, 2026
60Eversept Partners, LP16,5100 (0.00%)0.08%$0 MNov 16, 2026
61Palumbo Wealth Management LLC15,900-3,965 (-19.96%)0.08%$0 MNov 13, 2026
62Invesco Ltd.15,266+3,402 (+28.67%)0.07%$0 MNov 12, 2026
63Osaic Holdings, Inc.14,709+14,609 (+14609.00%)0.07%$0 MNov 12, 2026
64EntryPoint Capital, LLC14,702+6,417 (+77.45%)0.07%$0 MNov 13, 2026
65Virtus Investment Advisers, LLC13,821-430 (-3.02%)0.07%$0 MNov 12, 2026
66Rafferty Asset Management, LLC13,098New0.06%$0 MNov 13, 2026
67Rhumbline Advisers12,981+1,391 (+12.00%)0.06%$0 MNov 10, 2026
68Algert Global LLC11,570New0.06%$0 MNov 17, 2026
69Deutsche Bank AG\11,243+1,628 (+16.93%)0.05%$0 MNov 6, 2026
70Price T Rowe Associates Inc /MD/11,022+2,819 (+34.37%)0.05%$0 MNov 16, 2026
71Susquehanna International Group, LLP10,615New0.05%$0 MNov 16, 2026
72Dakota Wealth Management10,000New0.05%$0 MNov 12, 2026
73State Of Wisconsin Investment Board9,898New0.05%$0 MNov 16, 2026
74Two Sigma Investments, LP9,089-8,769 (-49.10%)0.04%$0 MNov 16, 2026
75MetLife Investment Management, LLC7,717+1,832 (+31.13%)0.04%$0 MNov 16, 2026
76Jpmorgan Chase & Co7,415-38,970 (-84.01%)0.04%$0 MNov 12, 2026
77MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.7,410+2,891 (+63.97%)0.04%$0 MNov 16, 2026
78Persistent Asset Partners Ltd6,132-810 (-11.67%)0.03%$0 MNov 13, 2026
79Vanguard Global Advisers, LLC5,686+1,071 (+23.21%)0.03%$0 MNov 13, 2026
80Citigroup Inc5,578+1,024 (+22.49%)0.03%$0 MNov 4, 2026
81Royal Bank Of Canada4,376+3,936 (+894.55%)0.02%$0 MNov 16, 2026
82New York State Common Retirement Fund4,2000 (0.00%)0.02%$0 MNov 17, 2026
83Police & Firemen's Retirement System of New Jersey3,763+856 (+29.45%)0.02%$0 MNov 9, 2026
84UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC2,784New0.01%$0 MNov 16, 2026
85Wells Fargo & Company/mn2,599-5,654 (-68.51%)0.01%$0 MNov 16, 2026
86Legal & General Group Plc1,226+268 (+27.97%)0.01%$0 MNov 16, 2026
87Ameritas Investment Partners, Inc.1,192+297 (+33.18%)0.01%$0 MNov 13, 2026
88State of Alaska, Department of Revenue989New0.00%$0 MOct 15, 2026
89Tower Research Capital LLC (TRC)970+440 (+83.02%)0.00%$0 MNov 16, 2026
90Russell Investments Group, Ltd.7880 (0.00%)0.00%$0 MNov 6, 2026
91Simplex Trading, LLC480New0.00%$0 MNov 4, 2026
92Sterling Capital Management LLC260+61 (+30.65%)0.00%$0 MOct 22, 2026
93Accent Capital Management, LLC2120 (0.00%)0.00%$0 MNov 12, 2026
94California State Teachers Retirement System1360 (0.00%)0.00%$0 MNov 13, 2026
95Global Retirement Partners, LLC67New0.00%$0 MNov 10, 2026
96EverSource Wealth Advisors, LLC59+4 (+7.27%)0.00%$0 MNov 4, 2026
97Parkside Financial Bank & Trust54New0.00%$0 MOct 27, 2026
98BFC Planning, Inc.410 (0.00%)0.00%$0 MNov 13, 2026
99GAMMA Investing LLC20New0.00%$0 MOct 8, 2026
100Allworth Financial LP19+9 (+90.00%)0.00%$0 MNov 17, 2026

All 104 institutional investors, with who bought and sold →

Mutual funds holding Assembly Biosciences, Inc.#

65 funds hold shares worth $44 M (about 7.9% of the company). Since their previous reports 54 added shares and 5 sold, buying $24 M net.
Mutual funds holding Assembly Biosciences, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.413,284$11 M2.0%<0.01%+19%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors244,994$7 M1.2%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.133,292$4 M0.65%<0.01%+2.5%Jun 30, 2026
🇺🇸 abrdn Healthcare Investorsabrdn Inc.129,708$4 M0.63%0.26%newJun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC107,386$3 M0.52%<0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors89,271$2 M0.44%0.02%newJun 30, 2026
🇺🇸 abrdn Life Sciences Investorsabrdn Inc.77,339$2 M0.38%0.31%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC58,396$2 M0.29%<0.01%−1.2%May 31, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.40,982$1 M0.20%0.09%newJul 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors33,135$1 M0.16%0.06%+43%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.23,781$1 M0.12%<0.01%newJul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC21,252$1 M0.10%<0.01%no changeMay 31, 2026
🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc.20,728$1 M0.10%0.08%newJun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC18,425$1 M0.09%<0.01%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC16,917$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.88,900$0 M0.09%0.04%no changeJul 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC13,750$0 M0.07%0.02%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC13,206$0 M0.06%<0.01%newJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC10,575$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC9,732$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust9,650$0 M0.05%<0.01%+58%May 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation7,300$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.6,351$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC6,716$0 M0.03%<0.01%+67%Jul 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.6,704$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.6,073$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC5,773$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.5,076$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.4,810$0 M0.02%<0.01%+38%Jun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.4,808$0 M0.02%0.03%−3.2%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC4,707$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC4,201$0 M0.02%0.01%newJun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC4,019$0 M0.02%<0.01%+3.0%Jul 31, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors3,547$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC3,337$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC2,793$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC2,237$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC2,230$0 M0.01%0.03%+34%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS2,164$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC2,020$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC2,020$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC1,791$0 M<0.01%0.01%+5.8%Jul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.1,547$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC1,665$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC1,512$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.1,504$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC1,322$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.1,441$0 M<0.01%<0.01%+20%Jul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust1,166$0 M<0.01%0.02%no changeMay 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC1,176$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.1,100$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC1,154$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management895$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC817$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC788$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS861$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC750$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC731$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC735$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC490$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC420$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC345$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC276$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC277$0 M<0.01%<0.01%−5.5%Jun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.249$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC61$0 M<0.01%<0.01%+5.2%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 66 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Assembly Biosciences, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$201 K
13 sales, 4 insiders
Net, 12 months
-$201 K
open market only
Insiders on file
22
since
$20.1 M-$187 K$0Nov 2023: bought $283 K (2 trades), sold $329 (1 trades)Nov 23Jan 2024: bought $510 K (2 trades), sold $0 (0 trades)Mar 2024: bought $0 (0 trades), sold $5 K (1 trades)MarApr 2024: bought $0 (0 trades), sold $60 K (6 trades)May 2024: bought $0 (0 trades), sold $43 K (4 trades)MayJun 2024: bought $0 (1 trades), sold $0 (0 trades)Jul 2024: bought $112 K (2 trades), sold $0 (0 trades)JulAug 2024: bought $0 (0 trades), sold $25 K (2 trades)Oct 2024: bought $146 K (1 trades), sold $5 K (2 trades)OctNov 2024: bought $372 K (3 trades), sold $652 (1 trades)Dec 2024: bought $20.1 M (2 trades), sold $0 (0 trades)DecMar 2025: bought $0 (0 trades), sold $15 K (4 trades)Aug 2025: bought $0 (1 trades), sold $0 (0 trades)AugMar 2026: bought $0 (0 trades), sold $14 K (4 trades)Jun 2026: bought $0 (0 trades), sold $674 (1 trades)JunNov 2026: bought $0 (0 trades), sold $187 K (8 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Assembly Biosciences, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jeanette M. BjorkquistPFO and PAOSell-718$19.61$14 K17,682Form 4
filed Anuj GaggarChief Medical OfficerSell-2,564$19.61$50 K53,829Form 4
filed Nicole S. WhiteChief Manufacturing OfficerSell-2,564$19.61—59,286Form 4
filed Jason A. OkazakiCEO and President, DirectorSell-6,133$19.61$120 K195,601Form 4
filed Jason A. OkazakiCEO and President, DirectorSell-69$20.35$1 K195,532Form 4
filed Anuj GaggarChief Medical OfficerSell-29$20.35$59053,800Form 4
filed Jeanette M. BjorkquistPFO and PAOSell-9$20.35$18317,673Form 4
filed Nicole S. WhiteChief Manufacturing OfficerSell-29$20.35—59,257Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Assembly Biosciences, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
3.0 M
19.1% of shares · 17 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-12 reverse split

Fails to deliver

  • : 2,907 shares at $21.19
  • : 2,727 shares at $34.07
  • : 4,381 shares at $32.13
  • : 283 shares at $32.95
  • : 51 shares at $26.44

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Assembly Biosciences, Inc. scorecard#

Passes 6 of the 16 checks that could be worked out: strongest in growth (2 of 3), weakest in profitability (1 of 4). Fiscal year 2025; market cap of Oct 21, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median2.1×Price to book 2.1× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median6.5×Price to sales 6.5× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-9.5%Free cash flow is -9.5% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth2 of 3
    • ✓Revenue grew in the newest year153.5%Revenue up 153.5% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.55 vs -6.69Diluted EPS -0.55 in fiscal 2025 against -6.69 the year before (report's currency).
    • ✓Net income higher than five years earlier-$6 M-$6 M in fiscal 2025 against -$62 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$6 MNet income -$6 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median-16.8%-16.8% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-5.1%-5.1% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities5.2×Current ratio 5.22 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone1.68Z-score 1.68 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year86.7%Diluted shares up 86.7% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Assembly Biosciences, Inc.'s statements, beside the median of Biotechnology.

Assembly Biosciences, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-16.8%-60.5%
Net margin-8.5%-68.9%
Return on equity-5.1%-61.0%
Revenue growth153.5%15.8%
Free cash flow margin-56.9%-61.5%

3of 7on the Piotroski tests of financial strength

  • Net loss of $6 million, the 17th loss-making year in a row.
  • Free cash flow was negative: -$41 million.
  • The share count rose 86.7% in the year.

Assembly Biosciences, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Assembly Biosciences, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue72297.206.37916159.00
Research and development6556497069107867344r33r
General and administrative201823242937333517r12r
Operating expenses8474729413914411910861—
Operating income−12−45−65−94−133−65−103−93−52r−45r
Other non-operating income (expense)6.05.63.51.00.32.64.33.10.4r0.4r
Income before tax−6.1−40−61−93−132−62−98−90−52r−45r
Income tax00.30.00−2.50−0.81.1−9.1r−0.6r
Net income including minority interests−6.1−40−61−93−130−62−98−91−43—
Net income attributable to shareholders−6.1−40−61−93−130−62−98−91−43r−44r
Earnings per share, basic-0.55-6.69-13.38-23.08r-3.00-1.75-3.72-3.98-2.41-2.57
Earnings per share, diluted-0.55-6.69-13.38-23.08r-3.00-1.75-3.72-3.98-2.41-2.57
Shares, weighted average (basic)116.04.64.0r43—————
Shares, weighted average (diluted)116.04.64.0r433526231817
Balance sheet
Cash and cash equivalents583820524659474182r29r
Short-term investments190741103910115722717738r24
Receivables1.000.00.90.31.23.42.42.3r0
Other current assets5.53.43.54.47.26.95.42.00.9r0.6
Current assets25511613497154224283223123r54
Property, plant and equipment0.20.30.40.71.11.61.80.60.9r0.2
Right-of-use (leased) assets2.53.12.33.26.09.1120——
Goodwill—————13131313r13
Other intangible assets————————2929
Non-current assets———————4646r45
Total assets258119137102191283340268169r98
Accounts payable1.20.60.52.52.74.61.73.7——
Current liabilities494839161624241813r7.1
Lease liabilities (non-current)2.12.61.10.13.36.79.10——
Non-current liabilities———————3943r11
Total liabilities518696192243675756r18
Retained earnings−832−826−786−725−631−502−439−342−251r−208
Shareholders' equity207334183169241273211113r80r
Total liabilities and equity258119137102191283340268169r98
Shares outstanding167.55.54.1r483433252017
Cash-flow statement
Depreciation and amortization0.10.10.50.50.50.70.50.60.2—
Share-based compensation4.73.15.16.65.22221288.6r5.0r
Cash from operating activities−41−5123−84−93−63−84−651.9r−35r
Capital expenditure−0.1−0.0−0.3−0.1−3.1−0.5−1.6−0.3−0.9r−0.1r
Acquisitions, net of cash acquired—————————0
Cash from investing activities−11340−69912768−50−135−16r36r
Shares issued1.92.04.50.3535.513515565—
Cash from financing activities17529140.6537.614016067r0.2r
Change in cash2019−336.8−14135.3−4153r1.5r
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Assembly Biosciences, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.5 M
Jason A. Okazaki
Other top executives, average
$1.3 M
the CEO earned 2× this
$100 invested is now
$218
Assembly Biosciences, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Jason A. Okazaki$2.5 M$5.5 M$1.3 M$218
2024Jason A. Okazaki$1.8 M$2.1 M$896 K$101
2023Jason A. Okazaki$1.4 M$1.1 M$759 K$63

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Assembly Biosciences, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Acquisition or sale completed 1 · Directors and officers 3 · Material agreement 6 · New debt 1 · Unregistered share sale 3 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 10

Assembly Biosciences, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K/A
Acquisition or sale completed8-K
Directors and officersShareholder vote8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementNew debt8-K
Material agreementUnregistered share sale8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Material agreementUnregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Assembly Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2010$3 MNo. 1$2 to $10 million44debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Assembly Biosciences, Inc.#

1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $233 K a year.

Certified, FY2025
1
#1,972 among companies on value.today
Worker positions
1
Median wage offered
$233 K
a year, full-time
Applications filed
1
Assembly Biosciences, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Senior Director, Discovery BiologyNatural Sciences Managers1$233 K

Where: South San Francisco, CA 1

Assembly Biosciences, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202511$233 K1
FY202111$88 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Assembly Biosciences, Inc.

Layoffs at Assembly Biosciences, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
30
2020–2022
Latest
30 people
2022-07-19
Assembly Biosciences, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2022······30·····30
2020············—
Assembly Biosciences, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
30 peopleRestructuring planSEC 8-K“The Plan includes a reduction of the Company’s workforce by 30 employees, resulting in a total of approximately 70 remaining employees.”Filing
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

Discuss Assembly Biosciences, Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 12 November 2026automatic update · Nov 12, 2026

    Assembly Biosciences, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $3 million (down 73% from a year earlier) and a net loss of $20 million.

  • Mutual funds: 65 funds hold $44 millionautomatic update · Jul 31, 2026

    65 mutual funds in 1 country hold shares of Assembly Biosciences, Inc. worth $44 million, about 7.9% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 54 funds added shares and 5 sold; on balance they bought $24 million. Share splits are not counted as trading.

How Assembly Biosciences, Inc. compares in Biotechnology

  • Market cap$434 M · higher than 56% of 726
  • Revenue$72 M · higher than 64% of 647
  • Net margin-16.6% · higher than 63% of 408
  • Revenue growth153.5% · higher than 87% of 438
  • Price / sales6.5× · lower than 56% of 339
  • Price / book2.1× · lower than 57% of 534
  • FCF yield-9.5% · higher than 58% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Assembly Biosciences, Inc.🇺🇸$434 M—-16.6%+153.5%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 21, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Assembly Biosciences, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Assembly Biosciences, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Assembly Biosciences, Inc.? Suggest a correction